<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03978117</url>
  </required_header>
  <id_info>
    <org_study_id>LMP-2018-25528</org_study_id>
    <secondary_id>2018NTLS144</secondary_id>
    <nct_id>NCT03978117</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Two Study Drinks in Detoxification of Environmental Toxicants and Carcinogens</brief_title>
  <official_title>Clinical Trial of Two Study Drinks in Detoxification of Environmental Toxicants and Carcinogens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this research is to determine if consuming one of two study drinks will help&#xD;
      enhance the detoxification of multiple environmental toxicants and cancer causing agents,&#xD;
      particularly in subjects who are null for glutathione-S-transferase M1 (GSTM1),&#xD;
      glutathione-S-transferase T1 (GSTT1), or both. If our research supports this idea, this drink&#xD;
      could be an inexpensive dietary component, which could promote good health.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 18, 2021</start_date>
  <completion_date type="Anticipated">September 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 15, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of study drink Preparation on toxins</measure>
    <time_frame>2 Months</time_frame>
    <description>Prevalence of environment toxins in study population</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of study drink Preparation on carcinogens</measure>
    <time_frame>2 Months</time_frame>
    <description>Prevalence of carcinogens in study population</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Freeze Dried Powder Preparation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Freeze dried Powder</intervention_name>
    <description>Freeze dried powder containing gluconasturtiin, which when added to a provided juice, will result in a target dose of up to 40 mg/day of 2-phenethyl isothiocyanate (PEITC). Preparation consumed at breakfast, lunch and dinner 3x daily for 2 weeks.</description>
    <arm_group_label>Freeze Dried Powder Preparation</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo Preparation</intervention_name>
    <description>Placebo powder added to a provided juice. Preparation consumed at breakfast, lunch and dinner 3x daily for 2 weeks.</description>
    <arm_group_label>Freeze Dried Powder Preparation</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult Male or female. Participants can be smokers or non-smokers&#xD;
&#xD;
          -  In good physical health&#xD;
&#xD;
          -  In stable and good mental health&#xD;
&#xD;
          -  Not using any medications that may affect the Nrf2 pathway&#xD;
&#xD;
          -  Women who are not pregnant or nursing or planning to become pregnant&#xD;
&#xD;
          -  Participants have provided written informed consent to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Significant immune system disorders, respiratory diseases, kidney or liver diseases or&#xD;
             any other medical disorders that may affect biomarker data as determined by the&#xD;
             licensed medical professional&#xD;
&#xD;
          -  Vital signs outside of the allotted range&#xD;
&#xD;
          -  Not willing to abstain from eating cruciferous vegetables during the course of the&#xD;
             study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dorothy Hatsukami, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephen Hecht, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Laboratory Medicine and Pathology, University of Minnesota</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hanna Vanderloo, RN, MSN</last_name>
    <phone>612.624.4983</phone>
    <email>hannav@umn.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hanna Vanderloo, RN, MSN</last_name>
    </contact>
    <investigator>
      <last_name>Dorothy Hatsukami, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>June 5, 2019</study_first_submitted>
  <study_first_submitted_qc>June 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2019</study_first_posted>
  <last_update_submitted>February 25, 2021</last_update_submitted>
  <last_update_submitted_qc>February 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

